Cue Health Seeks Authorization for Flu + COVID-19 Molecular Test

October 11, 2022

Cue Health has filed an Emergency Use Authorization (EUA) application to the FDA for its Cue Flu + COVID-19 molecular test for at-home and point-of-care use, hoping it can deploy its test within this respiratory infection season.

The test can simultaneously detect and differentiate between influenza and COVID-19 in approximately 25 minutes, with results delivered digitally to using the company’s Cue Health App.

If authorized, the test will be integrated into the company’s telehealth program — Cue Care — which enables users who test positive to seek prescribed COVID-19 treatment from a physician online.

View today's stories